Leadership Transition at Orion Corporation
Orion Corporation is undergoing an important change in its Executive Management Board. The company has confirmed the appointment of Mikko Kemppainen as General Counsel, effective June 1, 2025, as part of the leadership transition following the planned departure of Olli Huotari.
Details of the Management Change
Olli Huotari, Senior Vice President responsible for Corporate Functions, informed Orion about his decision to step down on May 31, 2025. As the new General Counsel, Mikko Kemppainen will be taking over key areas of responsibility previously held by Huotari, including Compliance, Intellectual Property Rights, Legal Affairs, and Public Affairs.
Mikko Kemppainen's Background
Mikko Kemppainen is well-prepared for this role due to his extensive experience at Orion, where he started as a Legal Counsel in 2006 before advancing to the Head of Legal Affairs. His educational background includes a Master of Laws degree from the University of Lapland, which he attained in 1998. Before joining Orion, Kemppainen built a solid foundation in legal practice with roles at Hannes Snellman Attorneys Ltd and the District Court of Tornio.
Messages from Leadership
Expressing her gratitude, President and CEO Liisa Hurme thanked Huotari for his years of service, noting his significant contributions to the company as a major asset. She highlighted the importance of having a candidate like Kemppainen, who was chosen from within the company and embodies Orion's vision for growth.
Leadership Insights
Liisa Hurme shared her confidence in Kemppainen’s abilities, stating, "I believe that Mikko’s long experience with Orion and from the pharmaceutical industry will be valuable in his new position. I look forward to working with him in the executive management board.” Kemppainen himself expressed enthusiasm about his new role, emphasizing his commitment to continue contributing to Orion's success.
Orion Corporation's Achievements
Orion Corporation is a well-established Finnish pharmaceutical company with a rich history spanning over a century, focusing on enhancing health through innovation. The company has a diverse product portfolio that includes both proprietary and generic pharmaceuticals and consumer health products. Their research and development efforts primarily target oncology and pain management, resulting in pioneering treatments for various medical conditions.
Current Status and Future Goals
In 2023, Orion reported net sales of EUR 1,190 million, employing around 3,600 people. The firm’s dedication to sustainable growth is apparent through its ongoing commitment to developing new treatments that align with modern healthcare needs. Under new leadership, Orion is set to navigate future challenges and opportunities within the pharmaceutical landscape.
Frequently Asked Questions
Who is the new General Counsel of Orion Corporation?
The new General Counsel appointed is Mikko Kemppainen, effective June 1, 2025.
What will be Kemppainen's responsibilities?
He will oversee Compliance, Intellectual Property Rights, Legal Affairs, and Public Affairs within the corporation.
Why is Olli Huotari leaving Orion Corporation?
Olli Huotari decided to leave the company, with his last day being May 31, 2025.
What is Orion Corporation's core focus in pharmaceuticals?
Orion focuses on developing treatments for oncology and pain management, amongst other therapeutic areas.
What was Orion Corporation's revenue in 2023?
Orion's net sales amounted to EUR 1,190 million in 2023.
